Savient: FDA clears drug for chronic gout - BusinessWeek

TopNews United Kingdom (blog)

Savient: FDA clears drug for chronic gout BusinessWeek The drug, dubbed Krystexxa, is made to treat adult gout patients who have failed to normalize serum uric acid. As a result, these patients' symptoms can't ... FDA Approves KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in ...MarketWatch (press release) Savient Gout Drug Wins FDA OK; Firm for SaleBioWorld Online Savient's big gamble pays off with approval of gout drugThe Star-Ledger - NJ.com Medscape -FierceBiotech -Examiner.com all 199 news articles »

Stock To Watch Today - SVNT - Penny Stock Live

Stock To Watch Today - SVNT Penny Stock Live The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes ... Savient Pharmaceuticals Announces Dismissal of Class Action LawsuitPR Newswire (press release) all 31 news articles »

Savient shares Shares at a 52 week high following chatter - Small Cap Network

Savient shares Shares at a 52 week high following chatter Small Cap Network SVNT recently received FDA approval of KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult ... FDA Approves New Gout Treatment KrystexxaRTT News Stock Rumors of the Day (Savient Pharmaceuticals, Brocade Communications , IBM)Benzinga all 21 news articles »

NASDAQ Stocks Volume Increase (MU, SVNT, NOVL, OREX, CYPB) - TooNiceStocks (blog)

NASDAQ Stocks Volume Increase (MU, SVNT, NOVL, OREX, CYPB) TooNiceStocks (blog) Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) – SVNT is a specialty biopharmaceutical company focused on developing treatments of chronic gout in patients ... and more »